Drug intelligence / Profile preview

MTS-118

Development stage: Preclinical
Lead developer: METiS Therapeutics

Overview

MTS-118 is a biologic drug candidate being developed by Metis Pharmaceuticals for the treatment of autoimmune diseases. The program is currently in the Investigational New Drug (IND)-enabling phase. Metis Pharmaceuticals leverages an integrated platform that combines artificial intelligence with advanced drug delivery technologies to optimize its pipeline candidates. While MTS-118 is categorized as a biologic for autoimmune indications, its specific biological target and detailed mechanism of action remain proprietary and have not been disclosed in available pipeline documentation.

Beyond the preview

Go deeper on MTS-118.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MTS-118.

Explore the full profile